Form 4: Sutro Biopharma Executive Anne Elizabeth Borgman Reports Stock Option and RSU Grants

Anne Elizabeth Borgman, Chief Medical Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) on March 5, 2024.

Summary

• Anne Elizabeth Borgman, Chief Medical Officer of Sutro Biopharma, filed a Form 4 on March 7, 2024, reporting changes in beneficial ownership.
• On March 5, 2024, Borgman acquired stock options for 60,000 shares of common stock at an exercise price of $4.54.
• These options vest monthly starting April 1, 2024, and will be fully vested by March 1, 2028, contingent upon continued service.
• Additionally, Borgman acquired 45,000 Restricted Stock Units (RSUs) on March 5, 2024.
• These RSUs vest annually, beginning on March 1, 2025, also contingent upon continued service, and each RSU represents one share of Sutro Biopharma's common stock.
• Following these transactions, Borgman directly owns 60,000 stock options and 45,000 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports standard executive compensation practices. The grants incentivize the executive, which is generally viewed positively, but it's a routine occurrence.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment to the company.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and amounts granted are generally benchmarked against peer companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates